In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in

Angela Camporeale1, Chaitanya Tellapragada1, Jelena Kornijenko1

  • 1Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutegrid.4714.6t, Stockholm, Sweden.

Microbiology Spectrum
|October 6, 2021
PubMed

Insights

Omadacycline shows promising in vitro activity against Clostridioides difficile, a growing cause of infection. Further clinical studies are needed to evaluate this novel antibiotic as a potential treatment option.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Clostridioides difficile infection (CDI) presents a significant and increasing clinical challenge.
  • Existing antibiotic treatments for CDI have limitations, including reduced efficacy and adverse side effects.
  • There is a critical need for novel and effective antimicrobial agents to combat CDI.

Purpose of the Study:

  • To evaluate the in vitro activity of omadacycline against contemporary isolates of Clostridioides difficile.
  • To compare the efficacy of omadacycline with other antibiotics against C. difficile.

Main Methods:

  • Agar dilution method was employed to assess antimicrobial activity.
  • A collection of 65 C. difficile isolates from Sweden (2015-2018) was used for testing.
  • Omadacycline and five comparator agents were tested against the isolates.

Main Results:

  • Omadacycline demonstrated in vitro activity against the tested Clostridioides difficile isolates.
  • The activity was observed across contemporary ribotypes of C. difficile.
  • Specific data on comparator agent activity is implied but not detailed in the abstract.

Conclusions:

  • Omadacycline exhibits promising in vitro activity against Clostridioides difficile.
  • Further clinical investigation is warranted to establish omadacycline's therapeutic potential for CDI.
  • The development of new treatments for CDI remains a priority.